Fluconazole Plus Amphotericin B Combinations Are Not Contraindicated and May Add Benefit for the Treatment of Candidemia

Odds, Frank C.
May 2003
Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1229
Academic Journal
Editorial. Presents the views of the author on the combination therapy of fluconazole and amphotericin (Am) B for the treatment of candidemia. Difficulties in the diagnosis of invasive fungal infections; Reference to the study conducted by John H. Rex et al and published in the May 15, 2003 issue of the journal 'Clinical Infectious Diseases,' on the combination of fluconazole and AmB for treatment of candidemia.


Related Articles

  • A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. Rex, John H.; Pappas, Peter G.; Karchmer, Adolf W.; Sobel, Jack; Edwards, John E.; Hadley, Susan; Brass, Corstiaan; Vazquez, Jose A.; Chapman, Stanley W.; Horowitz, Harold W.; Zervos, Marcus; McKinsey, David; Lee, Jeannette; Babinchak, Timothy; Bradsher, Robert W.; Cleary, John D.; Cohen, David M.; Danziger, Larry; Goldman, Mitchell // Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1221 

    A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other...

  • Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis. Gafter-Gvili, Anat; Vidal, Liat; Goldberg, Elad; Leibovici, Leonard; Paul, Mical // Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p1011 

    OBJECTIVE: To compare available antifungal treatments for invasive candidiasis, a leading cause of nosocomial bloodstream infections. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials that compared different antifungal agents for the treatment of...

  • Lipid Formulations of Amphotericins: Are You a Lumper or a Splitter? Wingard, John R. // Clinical Infectious Diseases;10/1/2002, Vol. 35 Issue 7, p891 

    Editorial. Analyzes the wisdom of grouping together lipid formulations of amphotericin as alternatives to conventional amphotericin B for empirical antifungal therapy. Pharmacokinetic differences in the formulations; Difference in mortality rates; Differences in efficacy.

  • Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open-Label Observational Study. Imhof, Alexander; Walter, Roland B.; Schaffner, Andreas // Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p943 

    Reports on amphotericin B deoxycholate (AmB-d) that remains a mainstay of antifungal therapy for immunocompromised patients, despite being associated with therapy-related toxicity. Median duration of AmB-d therapy; Possibility of dose escalation without delay in 28 patients.

  • Amphotericin B Deoxycholate Administered by Continuous Infusion: Does the Dosage Make a Difference? Hiemenz, John W. // Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p952 

    Focuses on amphotericin B deoxycholate (AmB-d) which has been the agent of choice for the treatment of patients who are at high risk for or who have documented invasive fungal infections. Decrease in the incidence of drug-related toxicity through the use of continuous infusion of conventional...

  • Antifungal Susceptibility of Bloodstream Candida Isolates in Sfax Hospital: Tunisia. Sellami, A.; Sellami, H.; Néji, S.; Makni, F.; Abbes, S.; Cheikhrouhou, F.; Chelly, H.; Bouaziz, M.; Hammami, B.; Ben Jemaa, M.; Khaled, S.; Ayadi, A. // Mycopathologia;Jun2011, Vol. 171 Issue 6, p417 

    Invasive candidiasis has emerged as an important nosocomial infection, causing significant morbidity and mortality especially among critically ill patients. The aim of our study was to determine specie distribution and resistance profiles of Candida species isolated from blood cultures....

  • Lipid-based Antifungal Agents Current Status. Arikan, Sevtap; Rex, John H. // Current Pharmaceutical Design;Mar2001, Vol. 7 Issue 5, p393 

    Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity...

  • Candida lusitaniae Infections in the Era of Fluconazole Availability. Hawkins, Jimmy L.; Baddour, Larry M. // Clinical Infectious Diseases;1/15/2003, Vol. 36 Issue 2, pe14 

    Amphotericin B resistance among isolates of Candida lusitaniae has distinguished it among Candida species. Because no comprehensive review has been published recently, we provide a case report and a literature review of C. lusitaniae infection to update and better characterize the illness in the...

  • Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever. Walsh, Thomas J.; Pappas, Peter; Winston, Drew J.; Lazarus, Hillard M.; Petersen, Finn; Raffalli, John; Yanovich, Saul; Stiff, Patrick; Greenberg, Richard; Donowitz, Gerald; Schuster, Mindy; Reboli, Annette; Wingard, John; Arndt, Carola; Reinhardt, John; Hadley, Susan; Finberg, Robert; Laverdière, Michél; Perfect, John; Garber, Gary // New England Journal of Medicine;1/24/2002, Vol. 346 Issue 4, p225 

    Background: Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative. Methods: In a randomized, international,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics